Associations between single nucleotide polymorphisms of COX-2 and MMP-2 genes and colorectal cancer susceptibility in the saudi population

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 12, 2014, Pages 4989-4994

  Shalaby, Manal Ali ^a   Nounou, Howaida Attia ^b   Alanazi, Mohammad Saud ^c   Alharby, Othman ^d   Azzam, Nahla ^d   Saeed, Hesham Mahmoud ^e  

^a City of Scientific Research and Technological Applications   (Egypt)

^b ALEXANDRIA UNIVERSITY   (Egypt)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^e ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Colorectal cancer; Cyclooxygenase; Matrix metalloproteinase; Single nucleotide polymorphism

Indexed keywords

CYCLOOXYGENASE 2; DNA; GELATINASE A; MMP2 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; BLOOD; CANCER STAGING; CASE CONTROL STUDY; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; RISK FACTOR; SAUDI ARABIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; RISK FACTORS; SAUDI ARABIA; TUMOR MARKERS, BIOLOGICAL;

EID: 84904663083     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.12.4989     Document Type: Article

References (53)

1. Amirian ES, Ittmann MM, Scheurer ME (2011). Associations between arachidonic acid metabolism gene polymorphisms and prostate cancer risk. Prostate, 71, 1382-9.
2. Asting G, Caren H, Andersson M, Lonnroth C, Lagerstedt K, Lundholm K (2011). COX-2 gene expression in colon cancer tissue related to regulating lactors and promoter methylation status. BMC Cancer, 11, 1-10.
3. Brown JR, DuBois RN (2005). COX-2: a molecular target lor colorectal cancer prevention. J Clin Oncol, 23, 2840-55.
4. Cahlin C, Lonnroth C, Arvidsson A, Nordgren S, Lundholm K (2008). Growth associated proteins in tumor cells and stroma related to disease progression ol colon cancer accounting lor tumor tissue PGE2 content. Int J Oncol, 32, 909-18.
5. Callejas NA, Casado M, Diaz-Guerra M (2001). Expression ol cyclooxygenase-2 promotes the release ol matrix metalloproteinase-2 and -9 in fetal rat hepatocytes. Hepatology, 33, 860-7.
6. Campa D, Zienolddiny S, Maggini V, et al (2004). Association ol a common polymorphism in the cyclooxygenase 2 gene with risk ol non-small cell lung cancer. Carcinogenesis, 25, 229-35.
7. Chun KS, Surh Y (2004). Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets lor chemoprevention. Biochem Pharmacol, 68, 1089-1100.
8. Chun S, Surh J (2014). Cancer chemoprevention targeting cox-2 using dietary phytochemicals, in 'Cancer and Inflammation Mechanisms: Chemical, Biological, and Clinical Aspects' (eds Y. Hiraku, S. Kawanishi and H. Ohshima), John Wiley & Sons, Inc., Hoboken, NJ, USA.
9. Church RD, Fleshman JW, McLeod HL (2003). Cyclooxygenase 2 inhibition in colorectal cancer therapy. Br J Surg, 90, 1055-67.
10. Chan AT, Ogino S, Fuchs CS (2007). Aspirin a n f he risk ol colorectal cancer in relation to the expression o COX-2. N EnglJMed, 356, 2131-42.
11. Cheng I, Liu X, Plummer SJ, et al (2007). COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer, 97, 557-61.
12. Chulada PC, Thompson MB, Mahler JF (2000). Genetic disruption ol Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res, 60, 4705-8.
13. Decock J, Paridaens R, Ye S (2008). Genetic polymorphisms ol matrix metalloproteinases in lung, breast and colorectal cancer. Clin Genet, 73, 197-211.
14. Dossus L, Kaaks R, Canzian F, et al (2010). PTGS2 and IL6 genetic variation and risk ol breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis, 31, 455-61.
15. Eberhart CE, Coffey PJ, Radhika A, et al (1994). Up-regulation ol cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107, 1183-8.
16. Ekambaram P, Lambiv W, Cazzolli R Ashton W, Honn V (2011). The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis. Cancer and Metastasis Reviews, 30, 397-408.
17. Fradet V, Cheng I, Casey G, Witte JS (2009). Dietary omega-3 latty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clin Cancer Res, 15, 2559-66.
18. Greenhough A, Smartt HJ, Moore AE, et al (2009): The COX-2/PGE2 pathway: key roles in the hallmarks ol cancer and adaptation to the tumour microenvironment. Carcinogenesis, 30, 377-86.
19. Gustalsson A, Hansson E, Kressner U, et al (2007). EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction ol disease-specific mortality. Int J Cancer, 121,232-40.
20. Gustalsson A, Hansson E, Kressner U, et al (2007). Prostanoid receptor expression in colorectal cancer related to tumor stage, differentiation and progression. Acta Oncol, 56, 1-6.
21. Hull MA, Ko SC, Hawcrolt G (2004). Prostaglandin EP receptors: targets lor treatment and prevention of colorectal cancer? Mol Cancer Ther, 3, 1031-39.
22. Hua H, Li M, Luo T, Yin Y, Jiang Y (2011). Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cellular and Molecular Life Sciences, 68, 3853-68.
23. Kessenbrock K, Plaks V, Werb Z (2010). Matrix metalloproteinases: regulators olthe tumor microenvironment. Cell, 141,52-67.
24. Lacchini, R, Jacob-Ferreira AL, Luizon MR, et al (2012). Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients. J Hum Hypertens, 26, 171-7.
25. Langsenlehner U, Yazdani-Biuki B, Eder T, et al (2006). The cyclooxygenase-2 (PTGS2) 8473T >C polymorphism is associated with breast cancer risk. Clin Cancer Res, 12, 1392-4.
26. Markowitz SD (2007). Aspirin and colon cancer-targeting prevention? N Engl J Med, 356, 2195-8.
27. Masferrer JL, Leahy KM, Koki AT, et al (2006). Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res, 60, 1306-11.
28. Menter DG, Schilsky RL, DuBois RN (2010). Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res, 16, 1384-90.
29. Oshima M, Dinchuk JE, Kargman SL (1996). Suppression of intestinal polyposis in Ape delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87, 803-9.
30. Oshima H, Oshima M, Inaba K (2004). Hyperplastic gastric tumours induced by activated macrophages in COX-21 mPGES-1 transgenic mice. EMBO J, 23, 1669-78.
31. Ozhan G, Lochan R, Leathart JBS, Charnley R Daly AK (2011). Cyclooxygenase-2 polymorphisms and pancreatic cancer susceptibility. Pancreas, 40, 1289-94.
32. Pereira C, Medeiros RM, Dinis-Ribeiro MJ (2009). Cyclooxygenase polymorphisms in gastric and colorectal carcinogenesis: are conclusive results available? Eur J Gastroenterol Hepatol, 21, 76-91.
33. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE (2002). Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vase Biol, 22, 1631-36.
34. Price SJ, Greaves DR, Watkins H (2001). Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp, in allele-specific transcriptional regulation. J Biol Chem, 276, 7549-58.
35. Ruud J, Nilsson A, Ruud L, Wang W, et al (2013). Cancerinduced anorexia in tumor-bearing mice is dependent on cyclooxygenase-1. Brain Behav Immun, 29, 124-35.
36. Sanger F, Nicklen S, Coulson AR (1977). DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci U S A, 74, 5463-7.
37. Shahedi K, Lindstrom S, Zheng SL, et al (2006). Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer, 119, 668-72.
38. Siironen P, Ristima'ki A, Nordling S (2004). Expression of COX-2 is increased with age in papillary thyroid cancer. Histopathology, 44, 490-7.
39. Sivula A, Talvensaari-Mattila A, Lundin J (2005). Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat, 89, 215-20.
40. Song F, Wang L, HuangY, et al (2013). MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells. Asian Pac J Cancer Prev, 14, 7529-36.
41. Thiel A, Narko K., Heinonen M, Hemmes A, Tomasetto C, Rio MC, Ristimaki A (2012). Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice. Int J Cancer, 131, 1032-41.
42. Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN (2006). Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol, 38, 1654-61.
43. Tsujii M, Kawano S, DuBois RN (1997). Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA, 94, 3336-40.
44. Wang X, Fu X, Brown PD, Crimmin MJ (1995). Foffman RM. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patientlike orthotopic model in a nude mice. Cancer Res, 54, 4726-8.
45. Wang D, Dubois RN (2006). Prostaglandins and cancer. Gut, 55, 115-22.
46. Wastson SA, Morris TM, Robinson G, et al (1995). Inhibition of organ invasion by the matrix metalloproteinase inhibitor BB-94 (batimastat) in two human colon carcinoma metastasis models. Cancer Res, 55, 3629-33.
47. Waston SA, Morris TM, Parsons SL, Steele PJC, Brown PD (1996). Therapeutic effect of matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model. Br J Cancer, 74, 1354-8.
48. Wu HC, Chang CH, Ke HL, et al (2011). Association of cyclooxygenase 2 polymorphic genotypes with prostate cancer in Taiwan. Anticancer Res, 31, 221-25.
49. Wu CY, Wang CJ, Tseng CC (2005). Helicobacter pylori promote gastric cancer cells invasion through a NF-kappaB and COX-2-mediated pathway, World J Gastroenterol, 11, 3197-203.
50. Xu E, Lai M, Lv B, et al (2004). A single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer. Biochem Biophys Res Commun, 324, 999-1003.
51. Zervos EE, Norman JG, Gower WR, Franz MG, Rosemurgy AS (1997). Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. J Sur Res, 69, 367-71.
52. Zhang X, Miao X, Tan W, et al (2005). Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology, 129, 565-76.
53. Zhao F, Zhu H, Huang M, Yi C, Huang Y (2013). The 765G> C polymorphism in the cyclooxygenase-2 gene and gastric cancer risk: an update by meta-analysis. Asian Pac J Cancer Prev, 15, 2863-8.